MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week hi
Post# of 71
Posted On: 11/14/2014 1:31:58 PM
MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week high of 10.50 Closing the day 09:44 at 10.40 -0.04 -0.38% With a day low of 10.35 and a total volume of 8,685.
MDXG Recent Posts: http://investorshangout.com/MiMedx-Group-Inc-MDXG-64149/
MDXG Mimedx Group Inc Recent Headline News
MiMedx elects Christopher M. Cashman as EVP
M2 - Mon Nov 10, 8:11AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) announced on Friday that it has appointed Christopher M. Cashman as its executive vice president & chief commercialisation officer.
MDXG: 10.39 (-0.05)
MiMedx® Adds New Executive
PR Newswire - Fri Nov 07, 8:39AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
MDXG: 10.39 (-0.05)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.01 (-0.06), OPK: 8.27 (-0.07), VNDA: 11.93 (-0.24), MDXG: 10.39 (-0.05), PDLI: 7.75 (-0.14)
MiMedx To Present At Two Healthcare Conferences
PR Newswire - Wed Nov 05, 1:59PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at two healthcare conferences in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014 at 11:30 am EST at the Palace Hotel. Management will also present at 8:00 am EST on Thursday, November 20, 2014, at the Canaccord|Genuity Forum, which is being held at the Westin Grand Central Hotel. Webcasts of each presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.39 (-0.05)
MiMedx raises full year 2014 guidance after Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:42AM CDT
MDXG: 10.39 (-0.05)
MiMedx Group's (MDXG) CEO Parker Petit on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 4:54PM CDT
MDXG: 10.39 (-0.05)
MiMedx Group beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:11AM CDT
MDXG: 10.39 (-0.05)
MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.39 (-0.05)
Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.39 (-0.05)
MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.39 (-0.05)
Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.39 (-0.05)
Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.39 (-0.05)
MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.39 (-0.05)
MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.39 (-0.05)
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 8.35 (-0.04), MYGN: 32.85 (-0.50), HALO: 8.48 (-0.26), MDXG: 10.39 (-0.05)
MiMedx Group's (MDXG) CEO Pete Petit Hosts Analyst Day (Transcript)
SA Transcripts - at Seeking Alpha - Tue Oct 14, 7:13PM CDT
MDXG: 10.39 (-0.05)
MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.39 (-0.05)
MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.39 (-0.05)
MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.39 (-0.05)
MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM"
allograft products to Zimmer to be marketed non- exclusively on a private label basis.
MDXG: 10.39 (-0.05)
MDXG Recent Posts: http://investorshangout.com/MiMedx-Group-Inc-MDXG-64149/
MDXG Mimedx Group Inc Recent Headline News
MiMedx elects Christopher M. Cashman as EVP
M2 - Mon Nov 10, 8:11AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) announced on Friday that it has appointed Christopher M. Cashman as its executive vice president & chief commercialisation officer.
MDXG: 10.39 (-0.05)
MiMedx® Adds New Executive
PR Newswire - Fri Nov 07, 8:39AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
MDXG: 10.39 (-0.05)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.01 (-0.06), OPK: 8.27 (-0.07), VNDA: 11.93 (-0.24), MDXG: 10.39 (-0.05), PDLI: 7.75 (-0.14)
MiMedx To Present At Two Healthcare Conferences
PR Newswire - Wed Nov 05, 1:59PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at two healthcare conferences in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014 at 11:30 am EST at the Palace Hotel. Management will also present at 8:00 am EST on Thursday, November 20, 2014, at the Canaccord|Genuity Forum, which is being held at the Westin Grand Central Hotel. Webcasts of each presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.39 (-0.05)
MiMedx raises full year 2014 guidance after Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:42AM CDT
MDXG: 10.39 (-0.05)
MiMedx Group's (MDXG) CEO Parker Petit on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 4:54PM CDT
MDXG: 10.39 (-0.05)
MiMedx Group beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:11AM CDT
MDXG: 10.39 (-0.05)
MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.39 (-0.05)
Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.39 (-0.05)
MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.39 (-0.05)
Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.39 (-0.05)
Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.39 (-0.05)
MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.39 (-0.05)
MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.39 (-0.05)
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 8.35 (-0.04), MYGN: 32.85 (-0.50), HALO: 8.48 (-0.26), MDXG: 10.39 (-0.05)
MiMedx Group's (MDXG) CEO Pete Petit Hosts Analyst Day (Transcript)
SA Transcripts - at Seeking Alpha - Tue Oct 14, 7:13PM CDT
MDXG: 10.39 (-0.05)
MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.39 (-0.05)
MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.39 (-0.05)
MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.39 (-0.05)
MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM"
allograft products to Zimmer to be marketed non- exclusively on a private label basis. MDXG: 10.39 (-0.05)
(0)
(0)